CRSPNEUTRAL

Return on Equity (ROE)

-30.3%

Higher than 12% of Healthcare sector peers

Updated 1078h ago

Sector Performance

12th percentile

CRSP

-30.3%

Sector Median

11.0%

Sector Avg

31.7%

📊

Deep Analysis

A Return on Equity (ROE) of -30.3% means that for every dollar of shareholder equity, CRISPR Therapeutics is generating a net loss of roughly 30 cents — a sign the company is not currently turning its capital into profit.

This is well below the healthcare sector median of 11.1%, placing the stock in the 12th percentile among peers, meaning 88% of sector companies have a higher ROE. The trend data is not available: the year-over-year change and quarter-over-quarter change are both listed as N/A, and the historical record shows only the current value. Without a trend, there is no information on whether the negative ROE is improving or worsening, which adds uncertainty. The combination of a deeply negative ROE and a lack of trend data signals elevated investment risk, as the company is failing to generate returns on equity and there is no track record to gauge progress. This metric contradicts any bullish outlook and supports the overall NEUTRAL verdict, since a negative ROE is typical for development-stage biotechnology firms but still reflects fundamental weakness that justifies a cautious stance.

Frequently Asked Questions

What does the Return on Equity (ROE) tell investors about CRSP?

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

How is the Return on Equity (ROE) calculated?

Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.

How does CRSP's Return on Equity (ROE) compare to its sector?

CRSP's Return on Equity (ROE) of -30.3% compares to a Healthcare sector median of 11.0%, placing it in the 12th percentile.

Who are CRSP's closest peers by Return on Equity (ROE)?

The closest Healthcare peers by Return on Equity (ROE) include: BIIB (7.7%), BDX (6.6%), ZBH (6.1%), TECH (5.3%), RVTY (3.2%).

The Formula

Net Income / Shareholders' Equity

Why It Matters

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.